Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
Farmers Insurance
Harvard Business School
Medtronic
Fish and Richardson
Baxter
Covington
UBS
Citi

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,001,861

« Back to Dashboard

Which drugs does patent 6,001,861 protect, and when does it expire?

Patent 6,001,861 protects MIRAPEX and is included in one NDA.

This patent has thirty-nine patent family members in twenty-five countries.
Summary for Patent: 6,001,861
Title: Use of pramipexole in the treatment of restless legs syndrome
Abstract:The present invention provides the use of pramipexole in the treatment of restless legs syndrome.
Inventor(s): Oertel; Wolfgang H. (Ranschenberg, DE), Meier; Dieter (Weisbaden, DE), Gomez-Mancilla; Baltazar (Portage, MI), Montplaisir; Jacques (Montreal, CA)
Assignee: Pharmacia & Upjohn Company (Kalamzoo, MI)
Application Number:09/008,212
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,001,861

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-001 Jul 1, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) ➤ Sign Up
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-002 Jul 1, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) ➤ Sign Up
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-006 Feb 12, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) ➤ Sign Up
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-007 Jul 30, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) ➤ Sign Up
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-003 Jul 1, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) ➤ Sign Up
Boehringer Ingelheim MIRAPEX pramipexole dihydrochloride TABLET;ORAL 020667-005 Jul 1, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,001,861

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,194,445 Use of pramipexole in the treatment of restless legs syndrome ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,001,861

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 281165 ➤ Sign Up
Australia 6016898 ➤ Sign Up
Australia 723119 ➤ Sign Up
Bulgaria 103543 ➤ Sign Up
Bulgaria 64614 ➤ Sign Up
Canada 2275379 ➤ Sign Up
China 1117564 ➤ Sign Up
China 1243439 ➤ Sign Up
Czech Republic 289863 ➤ Sign Up
Czech Republic 9902478 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Accenture
Boehringer Ingelheim
UBS
McKesson
Queensland Health
Citi
Farmers Insurance
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot